PEPG
PepGen Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 ▼ 3 insiders sell $57.6K at $6.23
- Mar 4 PepGen reported financial results for 2025 and provided updates on i…
- May 19 ▼ PepGen filed a new universal shelf registration statement (S-3) for…
- May 21 ▼ 1 insider sell $1.7K at $1.41
- May 22 ▼ PepGen's S-3 shelf registration (File No. 333-296016) became effecti…
- Jun 16 Craig-Hallum initiates
- Aug 6 ▲ PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus…
- Nov 10 Trading halt: Trading Halt: PEPG · T1 (News Pending)
- Nov 10 ▼ PepGen is offering $125 million in common stock and pre-funded warra…
- Nov 10 ▲ PepGen reported positive Phase 2 FREEDOM2-DM1 10 mg/kg cohort result…
- Nov 12 ▼ PepGen entered into an underwriting agreement for a $125 million pub…
- Nov 12 ▼ PepGen is offering 25,000,000 shares of common stock at $5.00 per sh…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $59.3K.
- InstitutionsMIXED
Q3 2026: 12 added (0 new), 10 trimmed or exited.
- AnalystsBULLISH
12 of 14 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.282 → −$0.312 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −11.5% to 3.37M shares. 2.8 days to cover, ≈4.9% of shares.
- TrendUPTREND
49% above its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 2 mentions: 1 bullish, 1 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $5.0M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $2.1M |
| JANE STREET GROUP, LLC | ADD | $718.0K |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | $603.5K |
| Qube Research & Technologies Ltd | DOUBLED | $482.9K |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | $438.1K |
| Squarepoint Ops LLC | NEAR_EXIT | $283.7K |
| Quadrature Capital Ltd | ADD | $137.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +258%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 11, 2026 | Wedbush MAINTAIN | Outperform |
| Sep 9, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jun 16, 2026 | Craig-Hallum INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
KEATING LAURIE Director Jun 18, 2026 | AWARD | 34,000 sh |
Dable Habib J Director Jun 18, 2026 | AWARD | 34,000 sh |
HENSON HEIDI Director Jun 18, 2026 | AWARD | 34,000 sh |
Finer Mitchell H. Director Jun 18, 2026 | AWARD | 34,000 sh |
Mayer Howard Director Jun 18, 2026 | AWARD | 34,000 sh |
Resnick Joshua Director Jun 18, 2026 | AWARD | 34,000 sh |
Wyman Lisa Director Jun 18, 2026 | AWARD | 34,000 sh |
RA CAPITAL MANAGEMENT, L.P. Director Jun 18, 2026 | AWARD | 34,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.27 | -$0.29–-$0.26 | -1.6% | $0.00 |
| Next Q | -$0.28 | -$0.32–-$0.22 | -10.0% | $0.00 |
| Current FY | -$1.08 | -$1.20–-$1.00 | +2.0% | $0.00 |
| Next FY | -$1.17 | -$1.78–-$0.81 | -10.7% | $0.00 |
Short side
FINRA· Oct 30, 2026| Nov 10, 2026 | Resumption Scheduled | Resumed |
SecBot reports
12 filings · 2 bullish · 5 bearish · 1 mixed · 4 neutral- BEARISH 8-KNov 12, 2026
PepGen entered into an underwriting agreement for a $125 million public offering of 25 million…
The $125 million offering more than doubles the company's cash position from $104.8 million to over $220 million, extending its runway into 2028. However, the massive dilution (25 million new shares…
- BEARISH 424B5Nov 12, 2026
PepGen is offering 25,000,000 shares of common stock at $5.00 per share in a priced underwritten…
The offering was priced at a premium to the prior close ($5.00 vs $4.61), suggesting strong underwriter demand, but the 36% dilution is substantial for a company with a $319M pre-offering market cap…
- BEARISH 424B5Nov 10, 2026
PepGen is offering $125 million in common stock and pre-funded warrants via an underwritten…
Monitor the final pricing and share count when the supplement is completed. The offering's size relative to market cap suggests substantial dilution; watch for the discount to the last sale price…
- BULLISH 8-KNov 10, 2026
PepGen reported positive Phase 2 FREEDOM2-DM1 10 mg/kg cohort results showing a mean splicing…
The 10 mg/kg data significantly de-risks PGN-EDODM1 and supports advancement toward pivotal studies. Key catalysts ahead: FREEDOM-OLE interim data in January 2027, 12.5 mg/kg cohort results in H1…
All PEPG filing & press-release reports (12)
- 8-K reportNov 12, 2026
- 424B5 reportNov 12, 2026
- 424B5 reportNov 10, 2026
- 8-K reportNov 10, 2026
- 8-K reportAug 6, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- EFFECT reportMay 22, 2026
- S-3 reportMay 19, 2026
- 8-K reportMay 12, 2026
- CLUSTER reportMar 4, 2026
- 8-K reportMar 4, 2026